Citalopram-induced hyponatraemia and parkinsonism: potentially fatal side-effects not to be missed

BMJ Case Rep. 2014 Nov 12:2014:bcr2014206575. doi: 10.1136/bcr-2014-206575.

Abstract

The use of selective serotonin reuptake inhibitors (SSRIs), such as citalopram, is on the rise and, as such, clinicians must be vigilant of rare side-effects associated with this group of medications. We report the case of a 65-year-old man who presented to West Suffolk Hospital with a fall, confusion and movement abnormalities, and was found to have a serum sodium of 105 on admission. He was managed with hypertonic saline, dopamine agonists and intensive physiotherapy. Despite initially deteriorating neurologically, he made a remarkable recovery, and was discharged home at his pre-admission baseline. The learning points from this report are as follows: (1) regular monitoring of electrolytes on starting an SSRI (and similarly selective noradrenaline reuptake inhibitors-SNRIs) in SSRI/SNRIs naïve patients, (2) awareness of possible citalopram-induced parkinsonism and the potential benefits of dopamine agonists as one management strategy and (3) vigilant fluid/electrolyte monitoring in patients with profound hyponatraemia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Citalopram / adverse effects*
  • Confusion / chemically induced
  • Humans
  • Hyponatremia / chemically induced*
  • Male
  • Parkinsonian Disorders / chemically induced*
  • Selective Serotonin Reuptake Inhibitors / adverse effects*

Substances

  • Serotonin Uptake Inhibitors
  • Citalopram